[HTML][HTML] Rapid response to cytokine storm inhibition using anakinra in a patient with COVID-19 myocarditis

C Trpkov, P MacMullan, P Feuchter, R Kachra… - CJC open, 2021 - Elsevier
C Trpkov, P MacMullan, P Feuchter, R Kachra, B Heydari, N Merchant, MS Bristow, JA White
CJC open, 2021Elsevier
A 62-year-old woman with coronavirus disease 2019 developed acute respiratory failure
and cardiogenic shock in the setting of a systemic hyperinflammatory state and apparent ST-
elevation myocardial infarction. Cardiac magnetic resonance imaging showed fulminant
acute myocarditis with severe left ventricular dysfunction. Treatment with the recombinant
interleukin-1 receptor antagonist anakinra and dexamethasone resulted in rapid clinical
improvement, reduction in serum inflammatory markers, and a marked recovery in cardiac …
Abstract
A 62-year-old woman with coronavirus disease 2019 developed acute respiratory failure and cardiogenic shock in the setting of a systemic hyperinflammatory state and apparent ST-elevation myocardial infarction. Cardiac magnetic resonance imaging showed fulminant acute myocarditis with severe left ventricular dysfunction. Treatment with the recombinant interleukin-1 receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers, and a marked recovery in cardiac magnetic resonance–-based markers of inflammation and contractile dysfunction. The patient was subsequently discharged from the hospital. Emerging evidence supports use of anti-inflammatory therapies, including anakinra and dexamethasone, in severe cases of coronavirus disease 2019.
Elsevier